Introducing NMDP, formerly known as the National Marrow Donor Program and Be The Match. Our name has changed but our mission has not: We save lives through cell therapy. Learn More

A drug, REGN7257, to treat severe aplastic anemia (SAA) that has come back (relapsed) or has not gotten better with treatment (refractory)


18 and older

Phase 1, Phase 2

2 Locations


Clinical Trial Goal

To find out:
  • The highest dose of REGN7257 that’s safe to give
  • If REGN7257 is safe and works well to treat SAA that has relapsed or is refractory

You may be able to join this trial if you:

  • Are 18 years old or older
  • Have SAA that has relapsed or is refractory after or during treatment with standard immunosuppressive therapy (IST)
  • Do not have Fanconi anemia (FA) or myelodysplastic syndrome (MDS)
  • Are not able to have an allogeneic (cells from a donor) blood or marrow transplant (BMT)
  • Have not been treated with alemtuzumab or anti-thymocyte globulin (ATG) in the last 6 months
  • Agree to have other standard tests done to see if you can be in the clinical trial 

Trial Details

REGN7257 is a monoclonal antibody that targets IL2 in certain cells.
You’ll get: 
  • REGN7257 – Given as intravenous (IV) infusions. The number of doses you'll get depends on when you start the trial and how safe it has been

You may continue treatment for as long as the clinical trial doctors think it’s best for your health. The doctors will check your health for up to 1.5 years.

The Food and Drug Administration (FDA) has not yet approved REGN7257.


Clinical Trials Administrator, 844-734-6643,


Cleveland Clinic FoundationActive, not recruiting

Cleveland, Ohio

The University of Texas MD Anderson Cancer CenterRecruiting

Houston, Texas record

NCT04409080. First posted on 6/1/20

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator